GlassScriptPhysician profile
Raul Almaguer
NPI 1134192131
$2,441.25
in general payments reported to CMS, 2019-2025
28 companies · $274 in 2025
The $274 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $662 · 2020: $451 · 2021: $260 · 2022: $172 · 2023: $209 · 2024: $412 · 2025: $274.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $801 · Education: $94.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $801.21 |
| Education | $94.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic Vascular, INC. | $645.00 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $155.25 | 2019-2025 | |
| Lilly USA, LLC | $154.20 | 2022-2025 | Mounjaro, Zepbound |
| Astrazeneca Pharmaceuticals LP | $116.77 | 2019-2020 | |
| Kowa Pharmaceuticals America, INC. | $112.26 | 2020-2025 | Zoryve |
| Actelion Pharmaceuticals US, INC. | $111.72 | 2024 | Uptravi, Opsumit |
| Amgen INC. | $110.92 | 2019-2025 | Repatha, Krystexxa |
| Janssen Pharmaceuticals, INC | $94.32 | 2019-2024 | Xarelto |
| Boston Scientific Corporation | $91.21 | 2021-2024 | Watchman Flx |
| Idorsia Pharmaceuticals US INC | $86.52 | 2023-2024 | Quviviq |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $82.24 | 2019-2022 | |
| Abbott Laboratories | $75.32 | 2021-2024 | Freestyle Libre 3 |
| Amarin Pharma, INC. | $72.05 | 2019-2022 | |
| Pfizer INC. | $69.88 | 2019-2025 | |
| Novo Nordisk INC | $63.76 | 2020-2021 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Edwards Lifesciences Corporation | $56.59 | 2023-2024 | |
| Avanir Pharmaceuticals, INC. | $56.02 | 2019 | |
| Exact Sciences Corporation | $52.95 | 2025 | Cologuard Collection Kit |
| Abbvie INC. | $41.33 | 2021 | |
| Allergan, INC. | $37.91 | 2019 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $31.56 | 2023 | Lifevest |
| Bayer Healthcare Pharmaceuticals INC. | $22.52 | 2022 | |
| Sumitomo Pharma America, INC. | $21.89 | 2025 | Gemtesa |
| Cvrx, INC. | $20.47 | 2024 | Barostim Neo System |
| E.R. Squibb & Sons, L.L.C. | $17.84 | 2021 | |
| Esperion Therapeutics, INC. | $16.02 | 2025 | Nexletol |
| Astellas Pharma US INC | $13.60 | 2020 | |
| Medtronic, INC. | $11.13 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Raul Almaguer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.